EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 17 Issue 1
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Editorial Archive

Conducting Clinical Trials in the Parallel Virtual Universe

Quantitative systems pharmacology (QSP) and physiologically based pharmacokinetic (PBPK) modelling can be employed to create a parallel virtual workflow throughout d...
19 April 2024 Editorial Archive | Volume 16 Issue 1 clinical | Conducting
Continue Reading →
Editorial Archive

Generative AI is Revolutionising Life Sciences, And We’re Just Scratching the Surface

On average, it takes about seven years to develop a new drug and bring it to market. For ambitious life science businesses, generative AI’s ability to generate insig...
19 April 2024 Editorial Archive | Volume 16 Issue 1 AI | clinical
Continue Reading →
Volume 15 Issue 4

Transparent, Pret-a-porter Operations Quality Measurement & Other 2024 Priorities for Drug Manufacturers & the Supply Chain

In Life Sciences manufacturing quality and compliance, the global digitalisation drive continues a-pace as the pressure builds to innovate, collaborate and contain c...
24 January 2024 Volume 15 Issue 4 contingency | drug
Continue Reading →
Volume 15 Issue 4

Diabesity: Implications for Treatment and Drug Development

The term “diabesity” has been used to refer to the twin pandemics of type 2 diabetes (T2D) and obesity.1 It was originally used after experiments showed that overfee...
24 January 2024 Volume 15 Issue 4 development | Diabesity
Continue Reading →
Volume 15 Issue 4

Developing Effective Supply Chain Strategies Utilising Forecasting Technology

Drug development has evolved considerably over recent decades, along with the clinical supply chains that underpin the continued advancement of human health. In t...
24 January 2024 Volume 15 Issue 4 chain | clinical supply chains
Continue Reading →
Regional News

Abzena nabs $65M to bolster manufacturing and research services on both sides of the pond

Roughly one year after dropping designs on a $200 million biologics plant in North Carolina, antibody-drug conjugate specialist Abzena has snared a fresh round of fun...
13 April 2022 Regional News Abzena | antibody
Continue Reading →
Regional News

Biogen’s Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst

During a January Q&A call with investors, Biogen chief Michel Vounatsos pressed Aduhelm supporters to fight the Centers for Medicare & Medicaid Services’ (CMS...
2 February 2022 Regional News Aduhelm | Biogen
Continue Reading →
Regional News

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties ...
2 February 2022 Regional News Amgen | drug
Continue Reading →
Regional News

Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe

Despite classwide safety worries in the U.S., AbbVie is making strides in its quest to build immunology up-and-comer Rinvoq. AbbVie sent off applications to U.S. and...
11 January 2022 Regional News AbbVie | drug
Continue Reading →
Regional News

After its $7.6B buyout fell through, Sobi scores NICE backing for rare disease drug Aspaveli

After rare disease drugmaker Sobi reportedly had a buyout scuppered by pharma giant AstraZeneca, the company has picked up a win that stands to bolster its Aspaveli l...
10 December 2021 Regional News Aspaveli | disease
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2025, All Rights Reserved – Powered by Teksyte